Two recent articles by the same research group documented that patients with severe eosinophilic asthma exhibit an increased proportion of a subtype of eosinophils, namely CD62L inflammatory eosinophils (iEos) and identified an intriguing correlation between such iEos and asthma control scores. Moreover, CD62L iEos were reduced after treatment with the anti-IL-5 monoclonal antibody mepolizumab. In the future, we believe that eosinophil subtypes could represent a useful biomarker in severe eosinophilic asthma, helping clinicians characterize patient endotypes and monitoring the response to biological drugs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285210PMC
http://dx.doi.org/10.2217/bmm-2023-0801DOI Listing

Publication Analysis

Top Keywords

severe eosinophilic
8
eosinophilic asthma
8
exploring novel
4
novel perspectives
4
perspectives eosinophilic
4
eosinophilic inflammation
4
inflammation severe
4
asthma
4
severe asthma
4
asthma articles
4

Similar Publications

IL-27 as a novel biomarker for pruritus in nodular prurigo and bullous pemphigoid.

Front Immunol

December 2024

Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Introduction: Bullous pemphigoid (BP) and prurigo nodularis (PN) are chronic pruritic skin diseases that severely impact patients' quality of life. Despite the widespread attention these two diseases have garnered within the dermatological field, the specific pathogenesis, particularly the molecular mechanisms underlying the pruritus, remains largely unclear. Limited clinical sequencing studies focusing on BP and PN have hindered the identification of pathological mechanisms and the exploration of effective treatment strategies.

View Article and Find Full Text PDF

Purpose: Although studies have evaluated benralizumab, a monoclonal IL-5 receptor α antibody in severe eosinophilic asthma (SEA), in real-world settings, additional evidence is needed to further characterize its effectiveness in specific patient populations. Our study aimed to evaluate asthma control over 56 weeks in patients treated with benralizumab in Swiss real-world settings.

Patients And Methods: Conducted across 13 centres, this prospective, observational, non-interventional study involved 73 adults with physician confirmed SEA.

View Article and Find Full Text PDF

Isotretinoin (13-cis-retinoic acid) is a well-established systemic treatment for moderate to severe acne vulgaris, renowned for its ability to target multiple contributors to acne pathogenesis. However, its therapeutic potential extends beyond conventional acne management. This case report highlights its efficacy in treating recalcitrant pustular dermatosis, a condition that proved resistant to standard therapies and posed significant diagnostic challenges.

View Article and Find Full Text PDF

Patients with severe eosinophilic asthma (SEA) can benefit from biologic therapy but some subjects may present an immune-mediated side effect. These patients will not meet the treatment goals and might have an increased risk of exacerbations. Monitoring these patients by determining blood eosinophil (BE) levels could be one of the tools that may allow a follow-up to prevent a worsening of asthma or exacerbations.

View Article and Find Full Text PDF

A novel herpesvirus in blue penguins putatively associated with myocardial degeneration and necrosis.

J Vet Diagn Invest

December 2024

Zoological Health Program, Wildlife Conservation Society, Bronx Zoo, Bronx, NY, USA.

We identified a novel herpesvirus in 2 deceased captive blue penguins (). Moderate-to-severe myocardiocyte atrophy and necrosis, and eosinophilic intranuclear inclusion bodies (INIBs), were seen in myocardiocytes in one bird; reticuloendothelial (RE) cell INIBs and multifocal RE cell necrosis were seen in both birds. The histologic findings were suggestive of viral infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!